Two Sigma Investments LP bought a new stake in Cellectis SA (NASDAQ:CLLS) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 10,792 shares of the biotechnology company’s stock, valued at approximately $180,000.
Several other hedge funds also recently bought and sold shares of the company. Financial Gravity Companies Inc. bought a new stake in Cellectis during the fourth quarter worth $71,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Cellectis by 37.6% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,545 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 1,787 shares during the period. KBC Group NV lifted its holdings in Cellectis by 22.9% during the fourth quarter. KBC Group NV now owns 14,266 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 2,661 shares during the period. Northern Trust Corp bought a new stake in Cellectis during the fourth quarter worth $301,000. Finally, JPMorgan Chase & Co. lifted its holdings in Cellectis by 24,158.5% during the third quarter. JPMorgan Chase & Co. now owns 48,517 shares of the biotechnology company’s stock worth $1,370,000 after acquiring an additional 48,317 shares during the period. Institutional investors own 27.61% of the company’s stock.
NASDAQ:CLLS opened at $20.00 on Wednesday. Cellectis SA has a 1 year low of $15.34 and a 1 year high of $31.57.
A number of analysts recently commented on the company. BidaskClub upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Friday, April 5th. ValuEngine upgraded Cellectis from a “sell” rating to a “hold” rating in a report on Monday, April 1st. William Blair assumed coverage on Cellectis in a report on Wednesday, March 13th. They set an “outperform” rating on the stock. Barclays reiterated a “buy” rating and set a $50.00 price target on shares of Cellectis in a report on Wednesday, March 13th. Finally, Citigroup dropped their price target on Cellectis from $37.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, March 11th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Cellectis presently has a consensus rating of “Hold” and an average target price of $32.00.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Read More: Golden Cross
Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.